Lithium: Updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder

CNS Drugs

Volumn 23, Issue 3, 2009, Pages 225-240

  Grandjean, Etienne Marc ^a   Aubry, Jean Michel ^b,c  

^a Phidalsa Institute for Clinical Investigation   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Department of Psychiatry   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CHLORAL HYDRATE; CHLORPROMAZINE; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; LORAZEPAM; OLANZAPINE; OXAZEPAM; PLACEBO; QUETIAPINE; RISPERIDONE; TEMAZEPAM; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTHYROIDISM; MANIA; METALLIC TASTE; MONOTHERAPY; MOOD DISORDER; MORTALITY; NAUSEA; PRIORITY JOURNAL; RAPID CYCLING BIPOLAR DISORDER; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SOMNOLENCE; SUICIDE; SYMPTOM; TASTE DISORDER; TREMOR; URINARY FREQUENCY; WEIGHT GAIN;

ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; EVIDENCE-BASED MEDICINE; HUMANS; LITHIUM COMPOUNDS; SUICIDE;

EID: 63149148333     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200923030-00004     Document Type: Review

References (81)

1. Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004 Jul; 5 (3): 120-35
2. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005 Jul; 66 (7): 870-86
3. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006 Dec; 8 (6): 721-39
4. Aubry JM, Ferrero F, Schaad N. Pharmacotherapy of bipolar disorders. Chichester: John Wiley & Sons, 2007.
5. Poolsup N, Li Wan Po A, de Oliveira IR. Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther 2000 Apr; 25 (2): 139-56
6. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994 Mar 23-30; 271 (12): 918-24
7. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005 Jan; 66 (1): 111-21
8. Bowden CL, Davis J, Morris D, et al. Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania. Depress Anxiety 1997; 6 (1): 26-30
9. Kushner SF, Khan A, Lane R, et al. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006 Feb; 8 (1): 15-27
10. Schou M, Juel-Nielsen N, Stromgren E, et al. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17: 250-60
11. Maggs R. Treatment of manic illness with lithium carbonate. Br J Psychiatry 1963; 109: 56-65
12. Emilien G, Maloteaux JM, Seghers A, et al. Lithium compared to valproic acid and carbamazepine in the treatment of mania: a statistical meta-analysis. Eur Neuropsychopharmacol 1996 Aug; 6 (3): 245-52
13. Keck PE Jr, Mendlwicz J, Calabrese JR, et al. A review of randomized, controlled clinical trials in acute mania. J Affect Disord 2000 Sep; 59 Suppl. 1: S31-7
14. Storosum JG, Wohlfarth T, Schene A, et al. Magnitude of effect of lithium in short-term efficacy studies of moderate to severe manic episode. Bipolar Disord 2007 Dec; 9 (8): 793-8
15. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998 May-Jun; 21 (3): 176-80
16. Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999 Nov; 14 (6): 339-43
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
18. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002 Jan; 59 (1): 62-9
19. Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomised controlled trial. Br J Psychiatry 2003 Feb; 182: 141-7
20. Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004 Dec; 24 (6): 599-606
21. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002 Jul; 159 (7): 1146-54
22. Reischies FM, Hartikainen J, Berghofer AM. Initial triple therapy of acute mania, adding lithium and valproate to neuroleptics. Pharmacopsychiatry 2002 Nov; 35 (6): 244-6
23. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000 May; 57 (5): 481-9
24. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003 Apr; 60 (4): 392-400
25. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003 Sep; 64 (9): 1013-24
26. Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004 Feb; 161 (2): 217-22
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association, 1987.
28. Prien RF, Caffey Jr EM, Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness: report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 1973; 28: 337-41
29. Kane JM, Quitkin FM, Rifkin A, et al. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982; 39: 1065-9
30. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989 Nov 30; 321 (22): 1489-93
31. Waters B, Lapierre Y, Gagnon A, et al. Determination of the optimal concentration of lithium for the prophylaxis of manic-depressive disorder. Biol Psychiatry 1982 Nov; 17 (11): 1323-9
32. Vestergaard P, Licht RW, Brodersen A, et al. Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels. Acta Psychiatr Scand 1998 Oct; 98 (4): 310-5
33. Greil W, Kleindienst N, Erazo N, et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998 Dec; 18 (6): 455-60
34. Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999 Sep; 14 (5): 277-81
35. Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999 Sep; 14 (5): 283-5
36. Hartong EG, Moleman P, Hoogduin CA, et al. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003 Feb; 64 (2): 144-51
37. Schou M. Lithium for affective disorders: cost and benefit. In: Ayd FJ Jr, Taylor IJ, editors. Mood disorders: the world's major public health problem. Baltimore (MD): AYD Medical Commun, 1978: 117-37
38. Keck PE Jr, Welge JA, Strakowski SM, et al. Placebo effect in randomized, controlled maintenance studies of patients with bipolar disorder. Biol Psychiatry 2000 Apr 15; 47 (8): 756-61
39. Tondo L, Baldessarini RJ, Hennen J, et al. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am J Psychiatry 1998 May; 155 (5): 638-45
40. Berghöfer A, Kossmann B, Muller-Oerlinghausen B. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years. Acta Psychiatr Scand 1996 May; 93 (5): 349-54
41. Bauer M, Ströhle A. Behandlungsstrategien bei prophylaxeresistenten bipolaren Storungen. Nervenarzt 1999 Jul; 70 (7): 587-99
42. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-8
43. Baethge C, Baldessarini RJ, Mathiske-Schmidt K, et al. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry 2005 Feb; 66 (2): 174-82
44. Solomon DA, Keitner GI, Ryan CE, et al. Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: a review. J Clin Psychopharmacol 1998 Feb; 18 (1): 38-49
45. Goldberg JF, Citrome L. Latest therapies for bipolar disorder: looking beyond lithium. Postgrad Med 2005 Feb; 117 (2): 25-6, 29-32, 35-6
46. Pies R. Combining lithium and anticonvulsants in bipolar disorder: a review. Ann Clin Psychiatry 2002 Dec; 14 (4): 223-32
47. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002 Apr; 159 (4 Suppl.): 1-50
48. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003 Jun; 17 (2): 149-73; discussion 7
49. McIntyre RS, Mancini DA, Lin P, et al. Treating bipolar disorder: evidence-based guidelines for family medicine. Can Fam Physician 2004 Mar; 50: 388-94
50. Suppes T, Dennehy EB, Swann AC, et al. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002 Apr; 63 (4): 288-99
51. NICE clinical guideline 38. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care [online]. Available from URL: www.nice.org.uk/CG038 [Accessed 2009 Feb 19]
52. Bauer M. Pharmakotherapie bei prophylaxeresistenten affektiven Störungen. In: Muller-Oerlinghausen B, Greil W, Berghofer A, editors. Die Lithiumtherapie-Nutzen-Risiken-Alternativen. 2 Aufl. ed. Berlin: Springer, 1997; 513-27
53. Jalfre V, Bayle FJ, Olie JP. Troubles bipolaires a cycles rapides: situation actuelle. Encephale 1999 May-Jun; 25 (3): 271-6
54. Post RM, Frye MA, Denicoff KD, et al. Emerging trends in the treatment of rapid cycling bipolar disorder: a selected review. Bipolar Disord 2000 Dec; 2 (4): 305-15
55. Kupka RW, Luckenbaugh DA, Post RM, et al. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry 2003 Dec; 64 (12): 1483-94
56. Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand 2003 Jul; 108 (1): 4-14
57. Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005 Nov; 162 (11): 2152-61
58. Coryell W. Rapid cycling bipolar disorder: clinical characteristics and treatment options. CNS Drugs 2005; 19 (7): 557-69
59. Goodwin FK. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J Clin Psychiatry 2003; 64 Suppl. 5: 18-24
60. Muzina DJ, Bauer M, Calabrese JR. Lithium in rapid cycling bipolar disorder. In: Bauer M, Grof P, Muller-Oerlinghausen B, editors. Lithium in neuropsychiatry: the comprehensive guide. Oxon: Informa, 2006: 145-155
61. Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgrad Med 2000 Apr; Spec No: 1-104
62. Krüger S, Trevor Young L, Braunig P. Pharmacotherapy of bipolar mixed states. Bipolar Disord 2005 Jun; 7 (3): 205-15
63. Hadjipavlou G, Mok H, Yatham LN. Pharmacotherapy of bipolar II disorder: a critical review of current evidence. Bipolar Disord 2004 Feb; 6 (1): 14-25
64. Yatham LN. Diagnosis and management of patients with bipolar II disorder. J Clin Psychiatry 2005; 66 Suppl. 1: 13-7
65. Nolen WA, Bloemkolk D. Treatment of bipolar depression, a review of the literature and a suggestion for an algorithm. Neuropsychobiology 2000; 42 Suppl. 1: 11-7
66. Silverstone PH, Silverstone T. A review of acute treatments for bipolar depression. Int Clin Psychopharmacol 2004 May; 19 (3): 113-24
67. Calabrese JR, Kasper S, Johnson G, et al. International Consensus Group on Bipolar I Depression treatment guidelines. J Clin Psychiatry 2004 Apr; 65 (4): 571-9
68. Prien RF, Klett CJ, Caffey EM. Lithium carbonate and imipramine in prevention of affective episodes: a comparison in recurrent affective illness. Arch Gen Psychiatry 1973; 29: 420-5
69. Guyatt G, Guttermann D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 2006; 129: 174-81
70. Goldsmith DR, Wagstaff AJ, Ibbotson T, et al. Lamotrigine: a review of its use in bipolar disorder. Drugs 2003: 63 (19): 2029-50
71. Fountoulakis KN, Vieta E, Sanchez-Moreno J, et al. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord 2005 May; 86 (1): 1-10
72. Möller HJ, Grunze H, Broich K. Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. Eur Arch Psychiatry Clin Neurosci 2006 Feb; 256 (1): 1-16
73. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders: part I. Treatment of bipolar depression. World J Biol Psychiatry 2002 Jul; 3 (3): 115-24
74. Malhi GS, Mitchell PB, Salim S. Bipolar depression: management options. CNS Drugs 2003; 17 (1): 9-25
75. Bauer M, Zaninelli R, Muller-Oerlinghausen B, et al. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J Clin Psychopharmacol 1999 Apr; 19 (2): 164-71
76. Nemeroff CB, Evans DL, Gyulai L, et al. Doubleblind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001 Jun; 158 (6): 906-12
77. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003 Sep 17; 290 (11): 1467-73
78. Nilsson A. Lithium therapy and suicide risk. J Clin Psychiatry 1999; 60 Suppl. 2: 85-8; discussion 111-6
79. Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006 Oct; 8 (5 Pt 2): 625-39
80. Cipriani A, Pretty H, Hawton K, et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005 Oct; 162 (10): 1805-19
81. Sondergard L, Lopez AG, Andersen PK, et al. Moodstabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord 2008 Feb; 10 (1): 87-94